US/UK/Canada

Share

About Us

ISR is an innovation-driven pharmaceutical research company in the field of immunotherapy. The company’s focus is on clinical and preclinical research with the goal of developing a broad-spectrum, antiviral therapy platform for immunomodulating drugs. www.israb.se Mangold Fondkommission is the company’s Certified Adviser and can be reached at +46 8 503 01 550.

Contacts

  • IR contact
    +46 73 308 00 34

    • Quotes

    The discoveries by Dr Allison and Dr Honjo are ground breaking for our understanding of the T-cell activation and regulation, findings which now have lead to the development of new treatment principles. For ISR this is a confirmation that we’re working in the very field, which this year is rewarded by the Nobel Prize. Tremendously stimulating!
    Ola Winqvist, CEO ISR
    We are excited to have started enrolment of patients. The study is unique, where ISR048s capacity to eradicate HIV virus carrying cells will be evaluated
    Ola Winqvist, CEO of ISR
    Pick a time period -
    Tags ( Active)

    ISR’s, SARS-CoV-2 dry powder nasal - vaccine booster candidate, ISR52, demonstrates superior immune response, in mouse model challenge studies compared to subcutaneous injection of this vaccine.

    The preclinical SARS-CoV-2 vaccine collaboration project between ISR (Immune System Regulation AB)  and Professor Ali Mirazimi, adjunct professor at the Department of Laboratory Medicine, Karolinska Institutet has now been published in the journal Vaccine.The mucosal immune system is the largest component of the entire immune system, having evolved to provide protection at the main sites of infectious threat: the mucosae. As SARS-CoV-2 initially infects the upper respiratory tract, its first interactions with the immune system must occur predominantly at the respiratory mucosal surfaces,

    SARS-CoV-2 vaccine study approved by Bangladesh BMRC

    ISR’s application to conduct a phase I/II clinical trial of the dry powder nasal vaccine for SARS-CoV-2 in Bangladesh has been approved.“We are very happy to have received approval from BMRC NREC for our nasal vaccine trial in Bangladesh. It has been a great team effort with the National Coordinating Investigators, professor ABM Abdullah, professor Ahmedul Kabir and professor Shafiqul Islam giving great support to the work of the local CRO, BCTL and laboratory icddr,b. Our next step is to complete the final steps of drug production as part of final approval. With the support from Dr

    ISR signs development agreements with Catalent to scale-up its spray-dried nasal vaccine, powder formulation for Phase III.

    ISR has signed agreements with Catalent to facilitate the development of its spray dried, SARS-CoV-2, dry powder, nasal vaccine, including and readiness for its phase III clinical campaign. Upon technical transfer to Catalent, the global leader in enabling pharma, and biotech partners to optimize product development, it will scale up production of the spray dried powder and provide analytical support from its Chelsea, Massachusetts, facility, which has extensive spray drying infrastructure and expertise necessary to meet clinical trial and commercial-scale volumes. “ISR has taken another

    ISR signs development agreements with Catalent to scale-up its spray-dried nasal vaccine, powder formulation for Phase III.

    ISR has signed agreements with Catalent to facilitate the development of its spray dried, SARS-CoV-2, dry powder, nasal vaccine, including readiness for its phase III clinical campaign. Upon technical transfer to Catalent, the global leader in enabling pharma, and biotech partners to optimize product development, it will scale up production of the spray dried powder and provide analytical support from its Chelsea, Massachusetts, facility, which has extensive spray drying infrastructure and expertise necessary to meet clinical trial and commercial-scale volumes. “ISR has taken another

    Delegation from Bangladesh visits ISR for study preparation

    ISR is hosting a workshop with a delegation from Bangladesh to prepare for the company’s phase I/II clinical trial of the dry powder nasal vaccine for SARS-CoV-2“We are very happy to have two national coordinating investigators here:  Professor ABM Abdullah, the prime minister’s personal physician, and Professor Shafiqul Islam, experienced vaccine coordinator from Dhaka,  Bangladesh, to coordinate our joint efforts to initiate the clinical trial. Their experience and expertise are highly appreciated ”, says CEO Ola Winqvist. The study is now in its final preparation phase where study

    ISR Holdings AB, enters important collaboration regarding Hepatitis B with Beijing Kawin Technology Share-Holding Co., Ltd.

    The board of ISR Immune System Regulation Holding AB (ISR) has signed a Memorandum of Understanding, with Beijing Kawin Technology Share-Holding Co., Ltd. (KAWIN), in order to develop ISRs immunolide ISR50 for Hepatitis B (HBV). ISR50 is a TLR agonist for an immunostimulatory treatment of HBV, a compound with a mode of action based on 2011 Nobel prize.Together with KAWIN, ISR will initiate pre-clinical testing in animal models of HBV evaluating the immunostimulatory properties of ISR50. KAWIN has received a Right of First Refusal (ROFR), which stipulates that KAWIN has the license for the

    The ISR Immunolide Platform Expanded into Hepatitis B

    Screenings of the substances from ISR’s Immunolide platform have identified a new pharmaceutical lead candidate, ISR051, which has immune stimulating effects, apparently advantageous in the treatment of hepatitis B. ISR now plans to expand its research and development portfolio to encompass, apart from HIV, tuberculosis and cancer, also hepatitis B.The hepatitis B virus (HBV) is one of the world’s most ubiquitous diseases, where WHO estimates over two billion people have or have had the disease and 240 million are chronic bearers. Nearly 700,000 people die in this disease every year, and 25%

    Activation of the Immune Defence in the Nobel Prize Focus

    The 2018 Nobel Prize in Physiology or Medicine awarded jointly to Dr. James P. Allison and Dr. Tasuku Honjo, highlights the significance of the immune system research. ISR is a company developing new immune stimulating pharmaceutical treatments of HIV, tuberculosis and cancer, with the help of the immune system.Our lead substance ISR048 stimulates two of the three pathways leading to T-cell activation, which can be further amplified and extended by adding pharmaceuticals inhibiting CTLA-4 and PD-1 (i.e. Checkpoint Blockage), the subjects of this year’s Nobel Prize. A phase II clinical trial

    First patient included into ISR’s Phase IIa HIV study

    As previously announced, ISR has a Phase IIa study of HIV-infected patients on anti-retroviral therapy (ART), where patients will be randomized to receive GnRH agonist (ISR048) in addition to ART, or ART alone. The first patient is now enrolled.ISR’s Phase IIa clinical study, ISR-003, is conducted at the Karolinska University Hospital Huddinge and at the South Hospital in Stockholm, SÖS. The study is composed of two arms with a total of 26+26 patients to be randomized into ART+ISR048 or to ART alone in the control group. Patients will be treated for 3 months and then followed for an

    ISR Immune System Regulation Holding AB starts two new programs against TBC and cancer

    Based on the concept of stimulating the immune system, ISR is currently developing a second line of immune-activating chemical entities together with the Cambridge based company Isomerase. The studies in the new indications will focus on TBC and cancer. Many bacteria and tumours have developed systems that help them avoid recognition and activation of the immune system. Therefore, there is a big and increasing medical need for immune stimulatory drugs. ISR-50, our IP protected lead drug candidate has enhanced immune stimulatory properties currently explored in vitro and in animal models

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe